Tresiba®, an insulin degludec injection, has received an expanded approval for the treatment of Type 1 diabetes in pediatric patients in Canada.
Tresiba ® is an ultra-long-acting basal insulin which provides a glucose-lowering effect beyond 42 hours.
“For children living with Type 1 diabetes, blood sugar control remains one of the most significant challenges of managing the disease,” said Dave Prowten, president and CEO, JDRF in a statement.
“We are pleased that this announcement means more individuals will have a new treatment option available to assist in combatting this challenge at all stages of the disease.”
Diabetes is the most frequently diagnosed endocrine disease occurring in children and is one of the most common chronic conditions among this group.
Annually, 86,000 children develop Type 1 diabetes globally, and Canada has one of the highest incidence rates for children under 14 years of age.
The expanded indication of Tresiba ® follows its first Health Canada approval in August 2017 for the treatment of adults with Type 1 and Type 2 diabetes mellitus.
Image Courtesy: Novo Nordisk.
- “Health Canada approves TRESIBA® for children with Type 1 diabetes.” October 1, 2018. Novo Nordisk Canada Inc. Retrieved: http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/News/TRESIBA_Expanded%20indication%20release_EN_FINAL.pdf